ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Wakamoto Pharmaceutical Co., Ltd. ?
1
Poor Management Efficiency with a low ROE of 0.95%
- The company has been able to generate a Return on Equity (avg) of 0.95% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of -6.53% over the last 5 years
3
With a growth in Net Sales of 9.38%, the company declared Very Positive results in Jun 25
- NET SALES(Q) Highest at JPY 2,168.55 MM
4
With ROE of 0.57%, it has a expensive valuation with a 0.91 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 52.56%, its profits have fallen by -54.2%
- At the current price, the company has a high dividend yield of 0.2
5
Market Beating Performance
- The stock has generated a return of 52.56% in the last 1 year, much higher than market (Japan Nikkei 225) returns of 38.59%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Wakamoto Pharmaceutical Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Wakamoto Pharmaceutical Co., Ltd. for you?
Medium Risk, Low Return
Absolute
Risk Adjusted
Volatility
Wakamoto Pharmaceutical Co., Ltd.
52.56%
0.67
43.48%
Japan Nikkei 225
38.59%
1.45
26.59%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-6.53%
EBIT Growth (5y)
9.03%
EBIT to Interest (avg)
-256.03
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.25
Sales to Capital Employed (avg)
0.67
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
161.58%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.35%
ROE (avg)
0.95%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
160
Industry P/E
Price to Book Value
0.91
EV to EBIT
-16.75
EV to EBITDA
-279.26
EV to Capital Employed
0.88
EV to Sales
0.98
PEG Ratio
NA
Dividend Yield
0.17%
ROCE (Latest)
-5.23%
ROE (Latest)
0.57%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend1What is working for the Company
NET SALES(Q)
Highest at JPY 2,168.55 MM
-27What is not working for the Company
INTEREST(HY)
At JPY 0.6 MM has Grown at 92.68%
PRE-TAX PROFIT(Q)
At JPY -117.48 MM has Fallen at -5,458.31%
NET PROFIT(Q)
At JPY -108.45 MM has Fallen at -759.76%
INVENTORY TURNOVER RATIO(HY)
Lowest at 1.61%
CASH AND EQV(HY)
Lowest at JPY 5,357.05 MM
DEBT-EQUITY RATIO
(HY)
Highest at -20.16 %
Here's what is working for Wakamoto Pharmaceutical Co., Ltd.
Net Sales
Highest at JPY 2,168.55 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (JPY MM)
Here's what is not working for Wakamoto Pharmaceutical Co., Ltd.
Interest
At JPY 0.6 MM has Grown at 92.68%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
Pre-Tax Profit
At JPY -117.48 MM has Fallen at -5,458.31%
over average net sales of the previous four periods of JPY 2.19 MMMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (JPY MM)
Net Profit
At JPY -108.45 MM has Fallen at -759.76%
over average net sales of the previous four periods of JPY 16.44 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (JPY MM)
Inventory Turnover Ratio
Lowest at 1.61% and Fallen
In each half year in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Cash and Eqv
Lowest at JPY 5,357.05 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debt-Equity Ratio
Highest at -20.16 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
